Atherosclerosis clinical trials at UCSF
4 in progress, 2 open to eligible people
Atherosclerosis is a condition where plaque builds up inside arteries. UCSF is examining how bempedoic acid might lower cholesterol in those with HIV. Another study is exploring if text message education can help people with HIV lower their heart disease risk.
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
open to eligible people ages 40 years and up
This is a randomized placebo-controlled study in treated and suppressed HIV-infected individuals aged ≥40 years with either known CVD or 1 CVD risk factor to study the effect of Bempedoic acid (BA) on safety, arterial inflammation as assessed by FDG-PET/CT, lipids, inflammation, immune activation, cardiometabolic indices, and non-calcified plaque (NCP) in the coronary arteries (assessed by coronary CT angiography, CCTA). This trial will be enrolled at UCSF and UCLA. Collaborators at Massachusetts General Hospital (MGH) will serve as the core facility for imaging.
San Francisco, California
Text Education About Cardiovascular Health and HIV (TEACH-HIV)
open to eligible people ages 40 years and up
The overall objective is to evaluate the efficacy of educational text messages to reduce cardiovascular risk among persons living with HIV (PLWH).
San Francisco, California and other locations
VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease
Sorry, not currently recruiting here
VictORION-INCLUSION (V-INCLUSION) seeks to evaluate the effectiveness of inclisiran as an innovative therapy with the potential to help bridge care gaps in historically understudied and undertreated populations by leveraging electronic health records (EHR) in multiple US Healthcare Systems (HCS) to systematically identify those at high risk for and already diagnosed with ASCVD for more expeditious achievement of LDL-C targets.
San Francisco, California and other locations
Mediators of Atherosclerosis in South Asians Living in America
Sorry, not currently recruiting here
South Asian (Indian, Pakistani, Bangladeshi, Nepali, and Sri Lankan) individuals have high rates of cardiovascular disease that is not explained by traditional cardiovascular risk factors. Though South Asians represent over one-quarter of the world's population, there are no longitudinal studies in this high-risk ethnic group. The investigators aim to establish a longitudinal study of South Asians at three United States centers to identify risk factors linked to subclinical atherosclerosis and incident cardiovascular disease. The purpose of this study is to understand the causes of heart disease and stroke in South Asians and compare these causes to those in other United States ethnic groups.
San Francisco, California and other locations
Our lead scientists for Atherosclerosis research studies include Priscilla Hsue, MD Megan McLaughlin, MD, MPH John Chorba, MD Alka Kanaya, MD.
Last updated: